Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) Return on Invested Capital (2023 - 2025)

Historic Return on Invested Capital for Protalix BioTherapeutics (PLX) over the last 3 years, with Q3 2025 value amounting to 0.1%.

  • Protalix BioTherapeutics' Return on Invested Capital rose 3200.0% to 0.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1%, marking a year-over-year increase of 3200.0%. This contributed to the annual value of 0.06% for FY2024, which is 2400.0% down from last year.
  • Latest data reveals that Protalix BioTherapeutics reported Return on Invested Capital of 0.1% as of Q3 2025, which was up 3200.0% from 0.13% recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Return on Invested Capital high stood at 0.13% for Q2 2025, and its period low was 0.29% during Q2 2024.
  • Its 3-year average for Return on Invested Capital is 0.01%, with a median of 0.08% in 2024.
  • Per our database at Business Quant, Protalix BioTherapeutics' Return on Invested Capital plummeted by -400bps in 2024 and then skyrocketed by 4200bps in 2025.
  • Over the past 3 years, Protalix BioTherapeutics' Return on Invested Capital (Quarter) stood at 0.11% in 2023, then tumbled by -35bps to 0.07% in 2024, then surged by 43bps to 0.1% in 2025.
  • Its Return on Invested Capital stands at 0.1% for Q3 2025, versus 0.13% for Q2 2025 and 0.08% for Q1 2025.